June 5, 2006
SpeculatingStocks.com Stock Pick: Genta, Inc. (GNTA)
Stock Price: $1.90 (short-term strong buy)
Genta, Inc. is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer.
With ASCO (American Society of Clinical Oncology) going on GNTA has begun to move. On Saturday, GNTA presented positive data from its lead anticancer drug, Genasense®, showing remissions are induced associated with the elimination of minimal residual disease (MRD). FDA approval of Genasense® is much more likely now with the latest data.
GNTA has $47.16 million in cash and short-term investments on its balance sheet. Total assets exceed total liabilities by a ratio of 6.31 to 1.
The company has grown revenue the past three years from $6.66 million in 2003 to $15.127 in 2004 to $26.585 million in 2005. Net loss has been reduced from $50.10 million to $32.68 million to a loss of only $2.20 million last year.
SpeculatingStocks.com Target Price: We expect GNTA to reach $3.00 within the next 1 to 2 months.